Scholar Rock wins first FDA approval for apitegromab (Isembyld) in spinal muscular atrophy

The FDA granted Scholar Rock approval for Isembyld (apitegromab-mstn), described as the first muscle-targeted treatment for spinal muscular atrophy in adults and children aged 2 and older. The approval marks the company's first FDA nod for the rare muscle-wasting disease.

Detected & updated continuously · Source: Nebula